Aadi Bioscience

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Aadi Bioscience sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 3 currently recruiting 5 completed early-phase tilt top decile by trial count

Aadi Bioscience: 9 sponsored US clinical trials, 3 recruiting.

Aadi Bioscience sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tumor, with 3 trials.

Top-decile sponsor footprint

Aadi Bioscience ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

NCT05997017
RECRUITING Phase 2

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

NCT05997056
RECRUITING Phase 1

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

NCT05661461
ACTIVE NOT RECRUITING Phase 2

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

NCT05103358
COMPLETED Phase 2

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

NCT03463265
COMPLETED Phase 1

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

NCT03439462
COMPLETED Phase 1

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

NCT02587325
COMPLETED Phase 2

A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

NCT02494570
COMPLETED Phase 1

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

NCT02009332

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5

Therapeutic Areas

Tumor 3
Tumor, Solid 2
Cancer 2
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma 1
Endometrioid Endometrial Cancer 1
Endometrioid Tumor 1
Tumors 1
Pulmonary Neuroendocrine Tumor 1
Gastrointestinal Neuroendocrine Tumor 1
NET 1

What is open in the Aadi Bioscience pipeline

3 recruiting of 9 indexed (33% open); 5 completed (56%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Tumor (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aadi Bioscience: open-pipeline peers nationwide

Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Aadi Bioscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40%50% Total trials Recruiting share Aadi Bioscience4D Molecular Therapeutics9 Meters BiopharmaAblynx, a Sanofi companyAcacia PharmaAaron CookAbivax S.A.Actuated MedicalAdagio Medical
Aadi Bioscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aadi Bioscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aadi Bioscience page

9 registered trials is a research-attention snapshot, not an endorsement of Aadi Bioscience or any single study.

  • 3 of Aadi Bioscience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tumor is the condition Aadi Bioscience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Aadi Bioscience pipeline card: 9 registered trials from official public datasets.Report a data error.